Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life

Movement Disorders : Official Journal of the Movement Disorder Society
Angelo AntoniniGianni Pezzoli

Abstract

We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction >/= 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.

References

Mar 1, 1994·International Clinical Psychopharmacology·J Hyttel
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
May 12, 2000·BMJ : British Medical Journal·H AllainN Mauduit
Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S TeseiG Pezzoli
Feb 9, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·UNKNOWN Global Parkinson's Disease Survey (GPDS) Steering Committee.
Jul 2, 2003·The American Journal of Psychiatry·Lon S SchneiderUNKNOWN Sertraline Elderly Depression Study Group
Aug 2, 2003·Biological Psychiatry·William M McDonaldMahlon R DeLong
Aug 18, 2004·Journal of Geriatric Psychiatry and Neurology·Albert F G Leentjens
Sep 21, 2004·The Journal of Neuropsychiatry and Clinical Neurosciences·Matthew MenzaMarc Lauritano

❮ Previous
Next ❯

Citations

Jul 3, 2013·Experimental Brain Research·Philippe Huot, Susan H Fox
Aug 15, 2009·Journal of Neural Transmission·Matthias LöhleHeinz Reichmann
Jul 10, 2007·Current Neurology and Neuroscience Reports·Irene Hegeman Richard
Jun 12, 2009·Current Neurology and Neuroscience Reports·John C Morgan, Kapil D Menza
Oct 17, 2013·Archives of Pharmacal Research·Hyun-Jung KimSun-Young Kong
Jan 6, 2012·The Neurologist·Oscar Bernal-PachecoHubert H Fernandez
Sep 18, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A Antonini
Jul 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J KulisevskyM Martínez-Corral
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Nov 30, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Barbara Connolly, Susan H Fox
Nov 13, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Silvia MarinoPaolo Di Bella
Nov 7, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·David GrimesUNKNOWN Canadian Nourological Sciences Federation
Mar 2, 2011·The British Journal of Psychiatry : the Journal of Mental Science·David TaylorUNKNOWN pharmacology subgroup of the National Institute for Health and Clinical Excellence Guideline Development Group for Depressi
Apr 7, 2016·Current Neurology and Neuroscience Reports·Jeffrey W Cooney, Mark Stacy
Mar 27, 2015·Parkinson's Disease·Philippe HuotJonathan M Brotchie
Oct 29, 2008·The American Journal of Medicine·Murray A Raskind
Oct 29, 2008·The American Journal of Medicine·Daniel E Ford
Jun 15, 2007·Expert Review of Neurotherapeutics·Leora L BorekJoseph H Friedman
Aug 28, 2007·Parkinsonism & Related Disorders·Francisco Javier Carod-ArtalPablo Martínez-Martin
Jan 23, 2017·Journal of the Neurological Sciences·Roberta Balestrino, Pablo Martinez-Martin
Jan 31, 2017·Journal of the Neurological Sciences·Roberta Balestrino, Pablo Martinez-Martin
Sep 18, 2015·Journal of Geriatric Psychiatry and Neurology·Massimiliano BuoliAlfredo Carlo Altamura
Aug 10, 2012·British Journal of Hospital Medicine·Javed LatooFrancis J Dunne
Oct 1, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katrina L PaumierTimothy J Collier
May 25, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Brenda L Den OudstenJolanda De Vries
Mar 20, 2013·Journal of Psychiatric Practice·Rosa Quelhas
Apr 9, 2009·Expert Opinion on Pharmacotherapy·Heinz Reichmann, Tjalf Ziemssen
May 24, 2019·Expert Opinion on Pharmacotherapy·Melody RyanJohn T Slevin
Nov 2, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Klaus SeppiCristina Sampaio
Dec 15, 2012·Expert Review of Neurotherapeutics·Barbara S Connolly, Susan H Fox
Mar 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Nicolas VeyresPhilippe Huot
Oct 18, 2019·Current Neuropharmacology·Francesca AssognaFrancesco E Pontieri
May 5, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Matthew MenzaAllison Dicke
Jun 26, 2013·Pharmacotherapy·Jack J Chen, Laura Marsh
Oct 24, 2007·British Journal of Hospital Medicine·D R S Jamieson, A E Jamieson
Apr 5, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Anna CastriotoPaul Krack
Dec 14, 2017·International Journal of Geriatric Psychiatry·Kelly A MillsGregory M Pontone
Aug 20, 2017·Current Neurology and Neuroscience Reports·Stephane ThoboisEmmanuel Broussolle
Aug 9, 2020·PLoS Computational Biology·Coryandar GilvaryOlivier Elemento
Jun 27, 2019·Expert Review of Neurotherapeutics·Isabella BerardelliGiovanni Fabbrini
Nov 10, 2020·Focus : Journal of Life Long Learning in Psychiatry·Susan K ConroyThomas W McAllister
Aug 28, 2021·International Journal of Environmental Research and Public Health·Elisabeth C DeMarcoLeslie Hinyard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.